Skip to main content
MorphoSys AG logo

MorphoSys AG — Investor Relations & Filings

Ticker · MOR ISIN · DE000A3H2XW6 LEI · 529900493806K77LRE72 F Manufacturing
Open in API
Filings indexed 1,418 across all filing types
Latest filing 2021-05-17 Declaration of Voting R…
Country DE Germany
Listing F MOR

About MorphoSys AG

https://www.morphosys.com/

MorphoSys AG is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines, primarily for cancer patients. The company specializes in creating therapeutic monoclonal antibodies, utilizing its long-standing expertise and proprietary technology platforms to generate fully human antibodies. Its research and development efforts are concentrated on building a pipeline of novel treatments to address significant unmet medical needs in oncology. In February 2024, Novartis entered into an agreement to acquire MorphoSys, aiming to integrate its antibody technologies and oncology pipeline.

Recent filings

Filing Released Lang Actions
Declaration of Voting Results & Voting Rights Announcements 2021
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled 'Voting Rights Announcements' and explicitly states 'Notification of Major Holdings' under German Securities Trading Act (WpHG) regulations. It details changes in the percentage of voting rights held by T. Rowe Price Group, Inc. and its subsidiaries, crossing specific thresholds (e.g., 4.71% direct voting rights). This content directly corresponds to the definition of reporting personal share transactions or changes in significant share ownership by major investors, which aligns best with the 'Major Shareholding Notification' category (MRQ). Although it mentions 'Voting Rights Announcements' in the header, the core content is the change in major shareholding percentage, not the results of a shareholder vote (DVA). It is not a director's dealing (DIRS) as the entity is an institutional investor, not an executive director, and the filing type is specifically about major holdings crossing thresholds.
2021-05-17 English
Declaration of Voting Results & Voting Rights Announcements 2021
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled 'Voting Rights Announcements' and explicitly states 'Notification of Major Holdings' under German Securities Trading Act (WpHG) regulations. It details the acquisition/disposal of shares and instruments by The Goldman Sachs Group, Inc., crossing specific voting rights thresholds (5.85% total). This type of filing, which reports changes in significant share ownership, directly corresponds to the definition of Major Shareholding Notification (MRQ). Although it is a regulatory announcement disseminated via DGAP, the specific content is about a major holding change, making MRQ the most precise classification over the general RNS.
2021-05-17 English
Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled 'Total Voting Rights Announcement' and explicitly mentions the 'Publication of total number of voting rights' and details a 'Type of capital measure' (Conditional capital increase) leading to a 'New total number of voting rights'. This type of mandatory disclosure regarding changes in the total number of shares/voting rights, often triggered by capital structure events, fits best under Capital/Financing Update (CAP) or potentially Regulatory Filings (RNS). Since it details a specific capital structure change (conditional capital increase) and the resulting voting rights count, it is more specific than a general RNS. However, none of the codes perfectly match 'Total Voting Rights Announcement'. Given the options, 'CAP' (Capital/Financing Update) is the most relevant category as it concerns the capital structure. If a more specific code for voting rights existed, it would be preferred. Given the context of German WpHG disclosure regarding capital measures, CAP is the strongest fit among the provided choices, although RNS is a possibility if CAP is strictly interpreted as fundraising.
2021-05-14 English
MorphoSys and Incyte Announce First Patient Dosed in Phase 3 frontMIND Study Evaluating Tafasitamab Combination as a First-line Treatment for Diffuse Large B-Cell Lymphoma
Legal Proceedings Report Classification · 1% confidence The document is a press release dated May 11, 2021, announcing that the first patient has been dosed in the Phase 3 *frontMIND* study for a drug combination. It details clinical trial progress, safety information, and company updates related to drug development and regulatory status (FDA/EMA). This type of announcement, focusing on clinical trial milestones and drug development news, is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is a detailed announcement of a specific corporate/clinical event rather than a summary of overall financial performance (ER) or a generic regulatory filing, and it is not a transcript, presentation, or formal report, it fits best as a general corporate announcement. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for detailed, non-financial-summary corporate news releases that don't fit other specific categories like DIV, CAP, or ER (which usually focus on quarterly/annual results). However, because it is a formal announcement of a significant corporate/clinical event, and it is not a summary of financial results (ER), it is classified as a general Regulatory Filing/Announcement.
2021-05-11 English
Q1 statement / Q1 financial report 2021
Interim / Quarterly Report Classification · 1% confidence The document is titled 'First Quarter Interim Statement' and covers the period of January–March 2021. It contains detailed financial results, including a Consolidated Statement of Profit or Loss, Balance Sheet, and Cash Flows, as well as operational and clinical development updates. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). Q1 2021
2021-05-10 German
MorphoSys AG Reports First Quarter 2021 Results
Earnings Release Classification · 1% confidence The document is titled "MorphoSys AG Reports First Quarter 2021 Results" and contains detailed financial tables for the '3M 2021' period, including revenues, operating loss, and EPS. It explicitly mentions 'Quarterly / Interim Statement' in the keywords and provides a full financial breakdown for a period shorter than a year (Q1 2021). This strongly indicates it is a comprehensive report for an interim period, fitting the definition of an Interim / Quarterly Report (IR). Although it announces a conference call, the bulk of the document is the financial results themselves, not just an announcement of the report's availability (which would be RPA/RNS). Q1 2021
2021-05-05 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.